Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults

Slides:

Advertisements

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Advertisements

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults

CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults

How to Treat MDS without Stem Cell Transplantation

Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells.

Biology of Blood and Marrow Transplantation

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

B Cells in Chronic Graft-versus-Host Disease

Adoptive Therapy with T Cells/NK Cells

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Transplantation of Umbilical Cord Blood–Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical.

Sabina Kersting, Leo F. Verdonck

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

A Comparison of the Kinetics of Nucleated Cells and CD34+ Cells in Neonatal Peripheral Blood and Cord Blood Joong-Pyo Kim, Young-Ho Lee, Young-Ah Lee,

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Paul Szabolcs, Donna Niedzwiecki

Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Sarah Nikiforow, Jerome Ritz

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

B Cells and Transplantation: An Educational Resource

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Statistical Considerations in Studies of Late Effects in HCT

Cellular Immune Reconstitution and Its Impact on Clinical Outcome in Children with β Thalassemia Major Undergoing a Matched Related Myeloablative Allogeneic.

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses Seitaro Terakura, Eiichi.

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Clinical Strategies to Enhance Posttransplant Immune Reconstitution

Pauline Damien, David S. Allan

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Richard Mitchell, John E. Wagner, Claudio G

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Karen K. Ballen, Thomas R. Spitzer, Beow Y

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

Sarah Nikiforow, Haesook T

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation Filippo Milano, Shelly Heimfeld, Ted Gooley,

Optimal Donor Selection: Beyond HLA

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation Lindsey E.

Presentation transcript:

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults Ioannis Politikos, Haesook T. Kim, Theodoros Karantanos, Julia Brown, Sean McDonough, Lequn Li, Corey Cutler, Joseph H. Antin, Karen K. Ballen, Jerome Ritz, Vassiliki A. Boussiotis Biology of Blood and Marrow Transplantation Volume 23, Issue 1, Pages 103-112 (January 2017) DOI: 10.1016/j.bbmt.2016.10.013 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kinetics of plasma VEGF, ANG-1, TM, and ANG-2 levels after dUCBT. (A-D) Median levels of VEGF (A), ANG-1 (B), TM (C) and ANG-2 (D) from baseline through 12 months post-transplantation are shown. Error bars denote 25th and 75th percentiles. Biology of Blood and Marrow Transplantation 2017 23, 103-112DOI: (10.1016/j.bbmt.2016.10.013) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 In vitro angiogenesis assay. (A) Representative images of HUVEC cells cultured with no serum (top row) or with two different concentrations of FCS (second and third row). FCS in the culture medium replaced by human plasma (bottom row). Biology of Blood and Marrow Transplantation 2017 23, 103-112DOI: (10.1016/j.bbmt.2016.10.013) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 In vitro angiogenesis assay and correlations with T cell subsets. (A) In vitro angiogenesis assay was performed using 2% plasma from each 1 of 21 dUCBT recipients and angiogenic activity after 18-hour incubation was quantified as described in Methods. Representative images of patients with high (pt1) and low (pt2) plasma angiogenic activity are shown. (B) Total segment length positively correlates with CD4+ (r = .45, P = .04), CD4+CD45R0+ (r = .49, P = .03), and CD4+CD25+ T cells (r = .49, P = .03) after dUCBT. Number of segments and meshes also positively correlated with T cell subsets and TRECs but fell short of statistical significance (data not shown). Biology of Blood and Marrow Transplantation 2017 23, 103-112DOI: (10.1016/j.bbmt.2016.10.013) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Median TM levels in patients with and without cGVHD. Patients who developed GVHD had higher TM levels at baseline (P < .001), at 4 weeks (P = .0045), 8 weeks (P = .01), and 100 days (P = .056) after dUCBT compared with patients without cGVHD. Biology of Blood and Marrow Transplantation 2017 23, 103-112DOI: (10.1016/j.bbmt.2016.10.013) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions